clinical trial · NCT07100730
Study of TLX101-Tx Plus Standard of Care (SoC) Versus SoC Alone for the Treatment of Patients With Recurrent Glioblastoma
Telix Pharmaceuticals (Innovations) Pty Limited·phase3·recruiting·n = 50
Neoplastic DiseaseGlioblastomaGlioblastoma (GBM)Glioblastoma MultiformGlioblastoma Multiforme, AdultGlioblastoma Multiforme (GBM) WHO Grade IVTLX-101-Tx + LomustineTLX101-Tx
brief summary
This global clinical trial which evaluates the efficacy and safety of TLX101-Tx, an investigational radiopharmaceutical therapy, in combination with lomustine versus lomustine alone in adult patients with first recurrence of glioblastoma. TLX101-Tx delivers targeted radiation to glioblastoma cells. The trial is conducted in two parts: Part 1 assesses safety and radiation dosing; Part 2 is a randomized comparison of the combination therapy against standard care.
started
Nov 2, 2025
primary completion
Jul 1, 2027
completion
Nov 1, 2027
last updated
Apr 16, 2026
official title
A Global, Multicenter, Prospective, Controlled, Open-Label Pivotal Study of Iodofalan (131I) Solution for Injection (TLX101-Tx) Plus Lomustine Versus Lomustine Alone in Patients With Radiographically Confirmed Recurrent Glioblastoma at First Recurrence (IPAX BrIGHT [IPAX-3])
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol